Menu
Not yet recruiting NCT07545174

Role of the Environment in Pediatric Obesity

No phase Interventional Obesity (Disorder)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Blood test, Urine sample, Hair sample.
Who it may be relevant to
Registry conditions: Obesity (Disorder). Basic parameters: 6 years — 15 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

Childhood obesity is a particular concern in developed countries such as the United States, the United Kingdom, Canada, and certain European countries. According to the World Health Organization (WHO), approximately 6% of children under the age of 5 worldwide were obese in 2016, a figure that continues to rise. The pathophysiology of pediatric obesity can be explained by several interconnected biological and behavioral mechanisms. In particular, it involves dysfunctions in the hormones that regulate appetite and satiety, as well as dysfunctions in lipid metabolism. Per- and polyfluoroalkyl substances (PFAS) are a large family of synthetic chemical compounds. The main PFAS are perfluorooctanoic acid (PFOA), perfluorooctanesulfonic acid (PFOS), perfluorononanoic acid (PFNA), and perfluorohexanesulfonic acid (PFHxS). PFAS are present in many everyday consumer products. Bisphenol A (BPA) is a chemical compound used primarily in the manufacture of plastics and resins. It is commonly found in polycarbonate plastics, used to make food containers and water bottles, as well as in epoxy resins, which are used to coat the inside of food cans and water pipes. Non-persistent pesticides, such as organophosphates and polychlorinated biphenyls, are chemicals used primarily in agriculture to control insects and other pests. There are arguments suggesting that PFAS, bisphenol A, and non-persistent pesticides may play a role in the onset of pediatric obesity, particularly by acting.

Interventions

  • Other Blood test
    Inclusion visit: during the routine blood test, one additional tube of blood will be collected for the study.
  • Other Urine sample
    Inclusion visit: a urine sample will be collected for the study.
  • Other Hair sample
    Inclusion visit: a hair sample will be taken from the patient.

Primary outcome measures

  • PFOA concentration [Time frame: At the enrollment visit]
Secondary outcome measures (6)
  • PFOS concentration [Time frame: At the enrollment visit]
  • PFNA concentration [Time frame: At the enrollment visit]
  • PFHxS concentration [Time frame: At the enrollment visit]
  • BPA concentration [Time frame: At the enrollment visit]
  • Non-persistent pesticides concentration [Time frame: At the enrollment visit]
  • Number of DNA breaks [Time frame: At the enrollment visit]

Eligibility criteria

Inclusion criteria

Patient with Obesity disorder :

  • Children with obesity (according to the BMI curves of the International Obesity Task Force/IOTF)
  • Follow-up within the obesity network of the Centre Val de Loire region (ObeCentre)

Control group:

  • Children who are not obese (according to the BMI curves of the International Obesity Task Force/IOTF)

All:

  • Children aged 6 to 15 at the time of inclusion (inclusive)
  • Whose two parents, or legal guardian, have signed an informed consent form
  • Patients affiliated with or covered by a social security system

Exclusion criteria

  • Disorder preventing understanding of trial information or informed consent.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Non-randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Basic science

Study locations

France · 2 centers
  • CHRU de Tours — Tours
  • CHRU de Tours — Tours

Identifiers

NCT: NCT07545174 · DR240165 · 2025-A01227-42

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗